Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Melding Deep Industry Experience with Commercial Insight

Companies operating in the healthcare and life sciences sectors face an increasingly complex transactional, political, and competitive landscape. Latham’s superior grasp of the regulatory regimes and market issues means that clients can adroitly and expeditiously address litigation, mergers and acquisitions, capital raising, regulatory counseling, business restructuring and reorganization, contract negotiations, fraud and abuse compliance, white collar and government investigations, operational matters, and more.


For more information on Latham’s Healthcare experience and expertise visit the Healthcare Services & Providers Industry Group page

Life Sciences

For more information on Latham’s Life Sciences experience and expertise visit the Life Sciences Industry Group page

Awards & Rankings

  • Latham Partners Honored for Leadership in Los Angeles - November 02, 2017
  • Two Partners Among “Top 40 Under 40” in California - April 17, 2017
  • Ten Partners Honored as 2016 MVPs - January 04, 2017
  • Two New York Litigators Earn Recognition as “Rising Stars” - June 16, 2016
  • Latham Earns “Health Group of the Year” Recognition - January 18, 2016
They are extremely focused on client relations. Whatever day or time, they made sure reviews were timely and their response was extraordinary.
— Chambers USA 2013


Webcast: Recent Developments in Health Care Enforcement

Media Coverage

A Strong Moral Compass: An Interview With Leslie CaldwellLeaders in Law: Healthcare Attorney of the Year - Manny A. AbascalUnitedHealth Beats DOJ's Medicare Advantage FCA Suit


Latham & Watkins Advises CVC on $703 Million Acquisition of TheramexImpact Biomedicines Advised in its Acquisition by Celgene Corporation Latham Partners Honored for Leadership in Los Angeles

Thought Leadership

FDA Issues Draft Guidance on Orphan Drug Designation in Pediatric SubpopulationsPharma and Biotech: Key Trends and Legal RisksFDA Reauthorization Act Aims to Speed Product Reviews Through User Fee Funding